Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02257567 2022-11-14

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

331 enrolled 81 charts 1 FDA

Lymphoid

Lymphoma

NCT00951457 2022-03-03

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Completed

20 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01535924 2021-11-19

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 1/2 Completed

26 enrolled 13 charts

Lymphoid

Hodgkin Disease, Recurrence

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, B-Cell

NCT01188681 2021-06-10

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Phase 1/2 Completed

79 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03259529 2021-06-07

BeGeRN

Phase 1/2 Completed

30 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

91 enrolled 27 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02059239 2021-02-21

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Phase 1/2 Completed

34 enrolled 22 charts

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT02799147 2020-11-23

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Phase 1/2 Completed

27 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01657331 2020-07-17

SGN+Benda

Phase 1/2 Completed

71 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT03343652 2020-05-28

NB001

Phase 1/2 Completed

30 enrolled

Lymphoid

Hodgkin Disease

NCT00987493 2019-05-15

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Phase 1/2 Completed

49 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1/2 Completed

55 enrolled 14 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01165112 2018-12-05

TREC

Phase 1/2 Completed

48 enrolled 9 charts

Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse

NCT00963534 2018-03-12

LENA-BERIT

Phase 1/2 Completed

51 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT01078142 2017-09-11

BERT

Phase 1/2 Completed

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT01412307 2015-08-11

LEBEN

Phase 1/2 Unknown

36 enrolled

Lymphoid

Hodgkin Disease

NCT00426855 2015-04-03

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Phase 1/2 Completed

12 enrolled 6 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

18 enrolled

Lymphoid

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01238146 2013-06-06

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00790855 2012-12-04

Bendamustine in Acute Leukemia and MDS

Phase 1/2 Terminated

27 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01221103 2011-09-13

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Phase 1/2 Unknown

50 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01170052 2011-03-16

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1/2 Withdrawn

20 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell